PROTACs: Walking through hematological malignancies
Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that uses the proteasome ubiquitin system to target proteins of interest and promote their degradation with remarkable selectivity. Importantly, unlike conventional small molecule inhibitors, PROTACs have proven highly e...
Main Authors: | Lara J. Bou Malhab, Habiba Alsafar, Saleh Ibrahim, Mohamed Rahmani |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1086946/full |
Similar Items
-
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
by: Yonghan He, et al.
Published: (2020-07-01) -
E3 ligase ligand optimization of Clinical PROTACs
by: Hanrui Jiang, et al.
Published: (2023-01-01) -
Synthesis and Biological Activity of a VHL-Based PROTAC Specific for p38α
by: Mónica Cubillos-Rojas, et al.
Published: (2023-01-01) -
Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
by: Arvind Negi, et al.
Published: (2022-11-01) -
Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
by: Sinan Ma, et al.
Published: (2022-07-01)